The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
A fresh patent battle has erupted over biosimilar entry for Eylea (aflibercept) in Japan. Bayer Yakuhin disclosed on November 12 — the day Fuji Pharma’s biosimilar won NHI listing — that originator firm Regeneron Pharmaceuticals has filed a request for…
To read the full story
Related Article
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Santen to Market Bayer’s Eylea Bio-AG; Launch Date Still Undisclosed
December 8, 2025
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Bayer’s Eylea Bio-AG Finally Reaches NHI Listing amid Reform Talks
December 4, 2025
- Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
November 17, 2025
- Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
November 11, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
- Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
- Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut
September 22, 2025
BUSINESS
- Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab
January 8, 2026
- Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Daito Snags China Approval for Iguratimod, Its Third Product
January 7, 2026
- China Accepts BLA for Leqembi Subcutaneous Autoinjector: Eisai
January 7, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…